Application of these state-of-the-art tools to NSCLC models could further clarify the dynamic regulation of CES3 and TFAP2A in the tumor microenvironment and identify biomarkers predictive of response to metabolism-targeted therapies. The gene discussed is TFAP2A; the disease is neoplasm.